Registered title, quoted from ClinicalTrials.gov
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 22 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 22
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
- Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
- Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
- Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
- Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
- Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
- Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
- Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
- Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07413939, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pathologically documented locally advanced inoperable (LAI) or metastatic breast cancer (MBC) with confirmed HER2-positive status by central laboratory.
Inclusion criterion 1
Measurable disease as per by RECIST v1.1 in stage 1. Non-measurable disease allowed in stage 2.
Inclusion criterion 2
At least one prior line of anti-HER2-based therapy for LAI or metastatic disease.
Inclusion criterion 4
Prior tyrosine kinase inhibitor (TKI) in the (neo)adjuvant setting provided completion is > 12 months ahead of LAI occurrence. Prior treatment with TKIs for LAI/MBC is not permitted.
Inclusion criterion 6
Concurrent anti-cancer treatment, or treatment with investigational therapy within 28 days prior to initiation of study treatment.
Exclusion criterion 1
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Inclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07413939, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Pathologically documented locally advanced inoperable (LAI) or metastatic breast cancer (MBC) with confirmed HER2-positive status by central laboratory.
- Measurable disease as per by RECIST v1.1 in stage 1. Non-measurable disease allowed in stage 2.
- Previously treated (stable or progressive) or previously untreated CNS metastases, or leptomeningeal metastases.
- At least one prior line of anti-HER2-based therapy for LAI or metastatic disease.
- Prior anti-HER2 antibody-drug conjugate (ADC), such as trastuzumab-deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1), in any treatment setting. Participants without prior ADC therapy may only be enrolled if approved standard-of-care (SOC) anti-HER2 ADC is not locally accessible at screening, or if there is a prospectively documented clinical contraindication.
- Prior tyrosine kinase inhibitor (TKI) in the (neo)adjuvant setting provided completion is > 12 months ahead of LAI occurrence. Prior treatment with TKIs for LAI/MBC is not permitted.
- Has protocol-defined adequate organ and bone marrow function.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Baseline left ventricular ejection fraction (LVEF) ≥ 50%.
Exclusion Criteria:
- Concurrent anti-cancer treatment, or treatment with investigational therapy within 28 days prior to initiation of study treatment.
- Known active/untreated hepatitis B or C or chronic liver disease.
- Clinically significant cardiovascular disease or risk, including heart failure (New York Heart Association (NYHA) ≥ II), ischemic heart disease or recent coronary events/interventions, clinically significant arrhythmias or electrocardiogram (ECG) abnormalities, QT prolongation or risk of ventricular dysrhythmias, poorly controlled hypertension, peripheral arterial disease, dilated cardiomyopathy, or unstable angina.
- Clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome.
- Concomitant use of any drug or herbal medicine known to strongly inhibit or induce CYP3A4 or CYP2C8 activity, oral coumarin-derivative anticoagulants.
Quoted from ClinicalTrials.gov, NCT07413939, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07413939, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.